Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 2/2020

09.08.2019 | Original Research

Genetic Changes of P53 and Kras in Gallbladder Carcinoma in Kumaon Region of Uttarakhand

verfasst von: Sanjeev Kumar Shukla, Govind Singh, Kedar Singh Shahi, Bhuvan, Prabhat Pant

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Gallbladder carcinoma is a highly lethal but relatively rare neoplasm of the digestive tract. p53 mutations are one of the most frequent genetic alterations in human cancers and are thought to play a role in pathogenesis of several malignancies. Kras oncogene is responsible for high frequency recognized as an early event in pancreatic and colonic carcinogenesis.

Objectives

We investigated the genetic change of p53, Kras and histopathological changes in gallbladder cancer tissue samples.

Methods

P53 mutation was seen in the axons 5, 6, 7 and 8 of p53 gene and Kras codon 12 mutations in 25 operative specimens of gallbladder carcinoma. The hispathology observations and polymerase chain reaction-based techniques of these patients were used for point mutations study in p53 and in codon 12 of Kras gene.

Results

Mutations of p53 analyzed from exons 5 to 8 using the method of PCR-SSCP were 44%, PCR-RFLP was carried out, and incidence of mutation in codon 12 of Kras was 48% in the adenocarcinoma patients. There was a significant correlation between presence of gall stone, histopathological type, cellular differentiation, grade, lymphovascular invasion, perineural invasion, lymph node invasion, involvement of cystic duct end margin, liver invasion, omental tissue invasion, and T.N.M. staging.

Conclusions

Curative surgical resection remains the only effective approach for treatment of GBC. Studies with large number of cases with latest application, next-generation sequencing, DNA microarray, transcriptome analysis, and real-time PCR would help in exploring more targets and better classification of these cancers at genetic level.
Literatur
1.
Zurück zum Zitat Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. J Clin Epidemiol. 2014;6:99–109. Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. J Clin Epidemiol. 2014;6:99–109.
2.
Zurück zum Zitat Misra S, Chaturvedi A, Goel MM, Mehrotra R, Sharma ID, Srivastava AN, et al. Overexpression of p53 protein in gallbladder carcinoma in North India. Eur J Surg Oncol. 2000;26:164–7.PubMedCrossRef Misra S, Chaturvedi A, Goel MM, Mehrotra R, Sharma ID, Srivastava AN, et al. Overexpression of p53 protein in gallbladder carcinoma in North India. Eur J Surg Oncol. 2000;26:164–7.PubMedCrossRef
3.
Zurück zum Zitat Chantarojanasiri T, Hirooka Y, Kawashima H, Ohno E, Kongkam P, Goto H. The role of endoscopic ultrasound in the diagnosis of gallbladder diseases. J Med Ultrasound. 2017;44(1):63–70. Chantarojanasiri T, Hirooka Y, Kawashima H, Ohno E, Kongkam P, Goto H. The role of endoscopic ultrasound in the diagnosis of gallbladder diseases. J Med Ultrasound. 2017;44(1):63–70.
4.
Zurück zum Zitat Murthy NS, Rajaram D, Gautham MS, Shivraj NS, Sreekantaiah P, Preethi SG, et al. Trends in incidence of gallbladder cancer-Indian scenario. Gastrointestinal Cancer. Target Ther. 2011;1:1–9. Murthy NS, Rajaram D, Gautham MS, Shivraj NS, Sreekantaiah P, Preethi SG, et al. Trends in incidence of gallbladder cancer-Indian scenario. Gastrointestinal Cancer. Target Ther. 2011;1:1–9.
5.
Zurück zum Zitat Sicklick JK, Fanta PT, Shimabukuro K, Kurzrock R. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev. 2016;35(2):263–75.PubMedPubMedCentralCrossRef Sicklick JK, Fanta PT, Shimabukuro K, Kurzrock R. Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design. Cancer Metastasis Rev. 2016;35(2):263–75.PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Nandakumar A, Gupta PC, Gangadharan P, Visweswara RN, Parkin DM. Geographic pathology revisited: development of an atlas of cancer in India. Int J Cancer. 2005;116:740–54.PubMedCrossRef Nandakumar A, Gupta PC, Gangadharan P, Visweswara RN, Parkin DM. Geographic pathology revisited: development of an atlas of cancer in India. Int J Cancer. 2005;116:740–54.PubMedCrossRef
7.
Zurück zum Zitat Kumari S, Tewari S, Husain N, Agarwal A, Pandey A, Singhal A, et al. Quantification of circulating free DNA as a diagnostic marker in gallbladder cancer. Pathol Oncol Res. 2017;23(1):91–7.PubMedCrossRef Kumari S, Tewari S, Husain N, Agarwal A, Pandey A, Singhal A, et al. Quantification of circulating free DNA as a diagnostic marker in gallbladder cancer. Pathol Oncol Res. 2017;23(1):91–7.PubMedCrossRef
8.
Zurück zum Zitat Shukla SK, Singh G, Shahi KS, Bhuvan PP. Staging, treatment and future approaches of gallbladder carcinoma. J Gastrointest Cancer. 2018;49(1):9–15.PubMedCrossRef Shukla SK, Singh G, Shahi KS, Bhuvan PP. Staging, treatment and future approaches of gallbladder carcinoma. J Gastrointest Cancer. 2018;49(1):9–15.PubMedCrossRef
9.
Zurück zum Zitat Li M, Chen L, Qu Y, Sui F, Yang Q, Ji M, et al. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing. Oncotarget. 2017;8(22):36319–30.PubMedPubMedCentral Li M, Chen L, Qu Y, Sui F, Yang Q, Ji M, et al. Identification of MAP kinase pathways as therapeutic targets in gallbladder carcinoma using targeted parallel sequencing. Oncotarget. 2017;8(22):36319–30.PubMedPubMedCentral
10.
Zurück zum Zitat Bodzioch S, Ogiela MR. New approach to gallbladder ultrasonic images analysis and lesions recognition. Comput Med Imaging Graph. 2009;33:154–70.PubMedCrossRef Bodzioch S, Ogiela MR. New approach to gallbladder ultrasonic images analysis and lesions recognition. Comput Med Imaging Graph. 2009;33:154–70.PubMedCrossRef
11.
Zurück zum Zitat Kumari S, Husain N, Agarwal A, Neyaz A, Gupta S, Chaturvedi A, et al. Diagnostic value of circulating free DNA integrity and global methylation status in gallbladder carcinoma. Pathol Oncol Res. 2018;1:12. Kumari S, Husain N, Agarwal A, Neyaz A, Gupta S, Chaturvedi A, et al. Diagnostic value of circulating free DNA integrity and global methylation status in gallbladder carcinoma. Pathol Oncol Res. 2018;1:12.
13.
Zurück zum Zitat Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.PubMedCrossRef Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67:93–9.PubMedCrossRef
14.
Zurück zum Zitat Japanese Society of Biliary Surgery. General rules for surgical and pathological studies on cancer of the biliary tract. 4th ed. Tokyo: Kanehara; 1997. Japanese Society of Biliary Surgery. General rules for surgical and pathological studies on cancer of the biliary tract. 4th ed. Tokyo: Kanehara; 1997.
15.
Zurück zum Zitat Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system (WHO classification of tumours volume 3), vol. 417. 4th ed. Lyon: IARC Press; 2010. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system (WHO classification of tumours volume 3), vol. 417. 4th ed. Lyon: IARC Press; 2010.
16.
Zurück zum Zitat Japanese Society of Biliary Surgery. General rules for surgical and pathological studies on cancer of the biliary tract. 5th ed. Tokyo: Kanehara; 2013. Japanese Society of Biliary Surgery. General rules for surgical and pathological studies on cancer of the biliary tract. 5th ed. Tokyo: Kanehara; 2013.
17.
Zurück zum Zitat Wang N, Xiang X, Chen K, Liu P, Zhu A. Targeting of NT5E by miR-30b and miR-340 attenuates proliferation, invasion and migration of gallbladder carcinoma. Biochimie. 2018;146:56–67.PubMedCrossRef Wang N, Xiang X, Chen K, Liu P, Zhu A. Targeting of NT5E by miR-30b and miR-340 attenuates proliferation, invasion and migration of gallbladder carcinoma. Biochimie. 2018;146:56–67.PubMedCrossRef
18.
Zurück zum Zitat Zulpo M, Balbus J, Kuropka P, Kubica K. A model of gallbladder motility. Comput Biol Med. 2018;93:139–48.PubMedCrossRef Zulpo M, Balbus J, Kuropka P, Kubica K. A model of gallbladder motility. Comput Biol Med. 2018;93:139–48.PubMedCrossRef
19.
Zurück zum Zitat Javle M, Rashid A, Churi C, Kar S, Zuo M, Eterovic AK, et al. Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol. 2014;45(4):701–8.PubMedCrossRef Javle M, Rashid A, Churi C, Kar S, Zuo M, Eterovic AK, et al. Molecular characterization of gallbladder cancer using somatic mutation profiling. Hum Pathol. 2014;45(4):701–8.PubMedCrossRef
20.
Zurück zum Zitat Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349–64.PubMedCrossRef Lazcano-Ponce EC, Miquel JF, Munoz N, Herrero R, Ferrecio C, Wistuba II, et al. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin. 2001;51:349–64.PubMedCrossRef
21.
Zurück zum Zitat Rashid A, Ueki T, Gao YT, Houlihan PS, Wallace C, Wang BS, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res. 2002;8:3156–63.PubMed Rashid A, Ueki T, Gao YT, Houlihan PS, Wallace C, Wang BS, et al. K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res. 2002;8:3156–63.PubMed
22.
Zurück zum Zitat Vousden KH, Lu X. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002;2:594–604.PubMedCrossRef Vousden KH, Lu X. Live or let die: the cell’s response to p53. Nat Rev Cancer. 2002;2:594–604.PubMedCrossRef
23.
Zurück zum Zitat Watanabe M, Asaka M, Tanaka J, Kurosawa M, Kasai M, Miyazaki T. Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroentero. 1994;107(4):1147–53.CrossRef Watanabe M, Asaka M, Tanaka J, Kurosawa M, Kasai M, Miyazaki T. Point mutation of K-ras gene codon 12 in biliary tract tumors. Gastroentero. 1994;107(4):1147–53.CrossRef
24.
Zurück zum Zitat Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res. 1995;55(12):2511–5.PubMed Wistuba II, Sugio K, Hung J, Kishimoto Y, Virmani AK, Roa I, et al. Allele-specific mutations involved in the pathogenesis of endemic gallbladder carcinoma in Chile. Cancer Res. 1995;55(12):2511–5.PubMed
25.
Zurück zum Zitat Ajiki T, Fujimori T, Onoyama H, Yamamoto M, Kitazawa S, Maeda S, et al. K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut. 1996;38:426–9.PubMedPubMedCentralCrossRef Ajiki T, Fujimori T, Onoyama H, Yamamoto M, Kitazawa S, Maeda S, et al. K-ras gene mutation in gall bladder carcinomas and dysplasia. Gut. 1996;38:426–9.PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Hanada K, Itoh M, Fujii K, Tsuchida A, Hirata M, Iwao T, et al. TP53 mutations in stage I gallbladder carcinoma with special attention to growth patterns. Eur J Cancer. 1997;33(7):1136–40.PubMedCrossRef Hanada K, Itoh M, Fujii K, Tsuchida A, Hirata M, Iwao T, et al. TP53 mutations in stage I gallbladder carcinoma with special attention to growth patterns. Eur J Cancer. 1997;33(7):1136–40.PubMedCrossRef
27.
Zurück zum Zitat Tanno S, Obara T, Fujii T, Mizukami Y, Shudo R, Nishino N, et al. Proliferative potential and K-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreaticobiliary ductal union. Cancer. 1998;83:267–75.PubMedCrossRef Tanno S, Obara T, Fujii T, Mizukami Y, Shudo R, Nishino N, et al. Proliferative potential and K-ras mutation in epithelial hyperplasia of the gallbladder in patients with anomalous pancreaticobiliary ductal union. Cancer. 1998;83:267–75.PubMedCrossRef
28.
Zurück zum Zitat Ahrendt SA, Rashid A, Chow JT, Eisenberger CF, Pitt HA, Sidransky D. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Sci. 2000;7:426–31.CrossRef Ahrendt SA, Rashid A, Chow JT, Eisenberger CF, Pitt HA, Sidransky D. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Sci. 2000;7:426–31.CrossRef
29.
Zurück zum Zitat Singh MK, Chetri K, Pandey UB, Kapoor VK, Mittal B, Choudhuri G. Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer. J Gastroenterol Hepatol. 2004;19:916–21.PubMedCrossRef Singh MK, Chetri K, Pandey UB, Kapoor VK, Mittal B, Choudhuri G. Mutational spectrum of K-ras oncogene among Indian patients with gallbladder cancer. J Gastroenterol Hepatol. 2004;19:916–21.PubMedCrossRef
30.
Zurück zum Zitat Cho NY, Choi M, Kim BH, Cho YM, Moon KC, Kang GH. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer. 2006;119:1858–62.PubMedCrossRef Cho NY, Choi M, Kim BH, Cho YM, Moon KC, Kang GH. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer. 2006;119:1858–62.PubMedCrossRef
31.
Zurück zum Zitat Nagahashi M, Ajioka Y, Lang I, Szentirmay Z, Kasler M, Nakadaira H, et al. Genetic changes of p53, K-ras and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary. W J Gastroenterol. 2008;14:70–5.CrossRef Nagahashi M, Ajioka Y, Lang I, Szentirmay Z, Kasler M, Nakadaira H, et al. Genetic changes of p53, K-ras and microsatellite instability in gallbladder carcinoma in high-incidence areas of Japan and Hungary. W J Gastroenterol. 2008;14:70–5.CrossRef
32.
Zurück zum Zitat Kazmi HR, Chandra A, Nigam J, Noushif M, Parmar D, Gupta V. Prognostic significance of K-ras codon 12 mutation in patients with resected gallbladder cancer. Dig Surg. 2013;30(3):233–9.PubMedCrossRef Kazmi HR, Chandra A, Nigam J, Noushif M, Parmar D, Gupta V. Prognostic significance of K-ras codon 12 mutation in patients with resected gallbladder cancer. Dig Surg. 2013;30(3):233–9.PubMedCrossRef
33.
Zurück zum Zitat Takagi S, Naito E, Yamanouchi H, Ohtsuka H, Kominami R, Yamamoto M. Mutation of the p53 gene in gallbladder cancer. Tohoku J Exp Med. 1994;172:283–9.PubMedCrossRef Takagi S, Naito E, Yamanouchi H, Ohtsuka H, Kominami R, Yamamoto M. Mutation of the p53 gene in gallbladder cancer. Tohoku J Exp Med. 1994;172:283–9.PubMedCrossRef
34.
Zurück zum Zitat Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD. p53 alteration in gastric precancerous lesions. Am J Pat. 1995;144(3):511–7. Shiao YH, Rugge M, Correa P, Lehmann HP, Scheer WD. p53 alteration in gastric precancerous lesions. Am J Pat. 1995;144(3):511–7.
35.
Zurück zum Zitat Puhalla H, Kandioler D, Ludwig C, Filipits M, Wrba F, Laengle F, et al. p53 analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry. Anticancer Res. 2004;24:1201–6.PubMed Puhalla H, Kandioler D, Ludwig C, Filipits M, Wrba F, Laengle F, et al. p53 analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry. Anticancer Res. 2004;24:1201–6.PubMed
36.
Zurück zum Zitat Itoi T, Watanabe H, Yoshida M, Ajioka Y, Nishikura K, Saito T. Correlation of p53 protein expression with gene mutation in gallbladder carcinomas. Pathol Int. 1997;47:525–30.PubMedCrossRef Itoi T, Watanabe H, Yoshida M, Ajioka Y, Nishikura K, Saito T. Correlation of p53 protein expression with gene mutation in gallbladder carcinomas. Pathol Int. 1997;47:525–30.PubMedCrossRef
37.
Zurück zum Zitat Yokoyama N, Hitomi J, Watanabe H, Ajioka Y, Pruyas M, Serra I, et al. Mutations of p53 in gallbladder carcinomas in high incidence areas of Japan and Chile. Cancer Epidemiol Biomark. 1998;7:297–301. Yokoyama N, Hitomi J, Watanabe H, Ajioka Y, Pruyas M, Serra I, et al. Mutations of p53 in gallbladder carcinomas in high incidence areas of Japan and Chile. Cancer Epidemiol Biomark. 1998;7:297–301.
38.
Zurück zum Zitat Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer. 1996;77:452–8.PubMedCrossRef Hanada K, Itoh M, Fujii K, Tsuchida A, Ooishi H, Kajiyama G. K-ras and p53 mutations in stage I gallbladder carcinoma with an anomalous junction of the pancreaticobiliary duct. Cancer. 1996;77:452–8.PubMedCrossRef
39.
Zurück zum Zitat Chaube A, Tewari M, Garbyal RS, Singh U, Shukla HS. Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients. BMC Cancer. 2006;10(6):126.CrossRef Chaube A, Tewari M, Garbyal RS, Singh U, Shukla HS. Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients. BMC Cancer. 2006;10(6):126.CrossRef
40.
Zurück zum Zitat Nigam P, Misra U, Negi TS, Mittal B, Choudhuri G. Alterations of p53 gene in gallbladder cancer patients of North India tropical. Gastroenterol. 2010;31(2):96–100. Nigam P, Misra U, Negi TS, Mittal B, Choudhuri G. Alterations of p53 gene in gallbladder cancer patients of North India tropical. Gastroenterol. 2010;31(2):96–100.
Metadaten
Titel
Genetic Changes of P53 and Kras in Gallbladder Carcinoma in Kumaon Region of Uttarakhand
verfasst von
Sanjeev Kumar Shukla
Govind Singh
Kedar Singh Shahi
Bhuvan
Prabhat Pant
Publikationsdatum
09.08.2019
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 2/2020
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-019-00283-0

Weitere Artikel der Ausgabe 2/2020

Journal of Gastrointestinal Cancer 2/2020 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.